Sun Pharma Must Face Celgene's Suit Over Generic Revlimid
Sun Pharma can't get out of Celgene's suit over a proposed generic version of the blockbuster cancer medication Revlimid, even though the patents in question aren't listed in the FDA's Orange...To view the full article, register now.
Already a subscriber? Click here to view full article